Investing in the future of mental and brain health
INVESTMENT FOCUS
Neurotech & BCI
Digital Health
Precision Neuroscience
Platforms & Novel Therapeutics
Alternative Modalities
PURPOSE
We fund and support founders revolutionizing brain and mental health through innovative neuroscience and frontier technologies. PsyMed founders align healing, responsibility, and profitability.
INVESTMENT FOCUS
We invest in frontier technologies transforming the mental and brain illness epidemic into a flourishing future.
ARTIFICIAL INTELLIGENCE
Advanced algorithms and machine learning to analyze vast data to enable early detection, accurate diagnosis, drug development and personalized treatment
NEUROTECH &
HUMAN AUGMENTATION
Direction connection of technical components with the brain and nervous system are addressing mental health disorders and neurological diseases
PRECISION PSYCHIATRY
Paradigm of clinical care shifting from general approach for large populations to individual-based deep knowledge of clinical and biological characteristics
DIGITAL THERAPEUTICS
Software applications that help patients treat, prevent, or manage a disease, and have a proven clinical benefit
HOLISTIC MEDICINE
Interconnection of biology, psychology, environment, and lifestyle, aiming to address root causes and promote overall well-being
METABOLIC PSYCHIATRY
Bidirectional relationship between metabolic processes and mental health, through diet, exercise, and gut microbiota can impact brain function and psychiatric disorders.
PSYCHEDELIC MEDICINE
& NEW COMPOUNDS
Psychedelics (i.e. psilocybin, MDMA, DMT, ketamine) or novel compounds to treat conditions including depression, addiction, PTSD, and more.
DIGITAL HEALTH
Mobile applications, wearables, and online platforms that enable remote access to mental health services, and facilitate data-driven personalized care
INVESTMENTS
IMYOO
Patient-centric immune biodiscovery platform
MOTIF NEUROTECH
Minimally invasive bioelectronic solutions for TRD
NEURODE
Non invasive neurostimulation and monitoring plafrom, starting with ADHD
SANMAI
Transcranial focused ultrasound for mental health
STEALTH MARKETPLACE
Marketplace for transformational mental health modalities
STEALTH NEUROTECH
Continuous hormone monitoring
STEALTH TECHBIO
Techbio platform for neuroinflammation
STEALTH TECHBIO
Programmable RNA splicing medicine for complex brain diseases
PEOPLE
Greg Kubin
General Partner & Co-Founder
Greg is a community builder, investor, and founder. He is a co-host of Business Trip, a podcast exploring the future of mental health and wellness. Over 20 investments in psychedelic medicine and mental health companies. Co-founded HelloSponsor, a SaaS sponsorship platform (AngelPad '15). Ex-Morgan Stanley, Viacom.
Matias Serebrinsky
General Partner & Co-Founder
Matias is an investor, founder, and startup ecosystem builder. He previously led NVIDIA Inception North America, an acelerator for AI startups. Before that, he co-founded CookUnity, a food+tech venture backed company that has delivered over one million meals to customers around the country. Matias is the co-host of Business Trip.
Dina Burkitbayeva
Co-Founder
Dina was one of the first investors in the psychedelic therapeutics space and is on the founding team of the largest psychedelic research center. Dina is also a serial entrepreneur, angel investor (Coinbase, Boom Supersonic, Mattermost), ex-McKinsey/J.P.Morgan, MBA Harvard Business School and MS in Psychology at CIIS.
Caitlin Ner
Director of Operations
Caitlin is an operator and community builder. She is also production lead of Business Trip. She was previously founding team of a seed stage AI startup, led insurance growth and operations at Cerebral, and alternative investing and asset management at BlackRock. Caitlin is ex-Harvard in Economics and Computer Science and a MSc Candidate in Applied Neuroscience at Kings College London.
Brooks Leitner MD PhD
Venture Partner
Brooks is an investor, founder and physician-scientist. He was previously founder of EpiTET Therapeutics targeting epigenetics to treat chronic disease. He was also a venture fellow at Foresite Capital, BrightEdge, and Canaan. Brooks is an MD PhD from Yale School of Medicine.
Building a company that’s elevating brain and mental health or looking to get involved as an investor?
SEND US AN EMAIL
